Alemtuzumab induction therapy in highly sensitized kidney transplant recipients

Chinese Medical Journal

Volumn 124, Issue 5, 2011, Pages 664-668

  Lü, Tie Ming ^a   Yang, Shun Liang ^a   Wu, Wei Zhen ^a   Tan, Jian Ming ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Alemtuzumab; Antithymocyte globulin; Immune induction; Kidney transplantation; Panel reactive antibody

Indexed keywords

ALEMTUZUMAB; CREATININE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROGEN; PANEL REACTIVE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY; UREA;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CAUSE OF DEATH; CHILL; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; FOLLOW UP; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LUNG INFECTION; MALE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RIGOR; SINGLE DRUG DOSE; SURVIVAL RATE; URINARY TRACT INFECTION; VIRUS INFECTION; WOUND INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952500113     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.05.005     Document Type: Article

References (20)

1. Scientific Registry of Transplant Recipients. 2008. (Accessed at http://www.ustransplant.org. OPTN/SRTR Annual report.)
2. Shapiro R, Basu A, Tan H, Gray E, Kahn A, Randhawa P, et al. Kidney transplantation under miniamal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505-515.
3. Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S, et al. Campath-1H induction and the incidence of infectious complications in adult kidney transplantation. Transplantation 2006; 81: 17-20.
4. Wang D, Wu WZ, Yang SL, Chen JH, Tan JM. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized kidney transplant recipients. Chin Med J 2006; 119: 1683-1688.
5. Tippner C, Nashan B, Hoshino K, Schmidt-Sandte E, Akimaru K, Böker KH, et al. Clinical and subclinical acute rejection early after liver transplantation: contributing factors and relevance for the long-term course. Transplantation 2001; 72: 1122-1128.
6. Woodside KJ, Hu M, Meng T, Hunter GC, Sower LE, Daller JA, et al. Differential effects of interleukin-2 blockade on apoptosis in naive and activated human lymphocytes. Transplantation 2003; 75: 1631-1635.
7. Magliocca JF, Knechtle SJ. The evolving role of Campath-1H (Alemtuzumab) for immunosuppressive therapy in organ transplantation. Transplant Int 2006; 19: 705-714.
8. Ciancio G, Burke GW 3rd. Campath-1H (Alemtuzumab) in kidney transplantation. Am J Transplant 2008; 8: 15-20.
9. Akalin E. Posttransplant immunosuppression in highly sensitized patients. Contrib Nephrol 2009; 162: 27-34.
10. Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, et al. A randomized trial of three kidney transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457-465.
11. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP, et al. Campath-1H induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction long-term results. Am J Transplant 2005; 5: 2539-2548.
12. Shou ZF, Zhou Q, Cai JR, Cheng J, He Q, Wu JY, et al. Efficacy and safety of induction therapy with Campath-1H in kidney transplantation: a meta-analysis. Chin Med J 2009; 122: 1692-1698.
13. Shapiro R, Basu A, Tan HP, Morgan C, Sharma V, Blisard D, et al. Kidney after nonrenal transplantation-the impact of alemtuzumab induction. Transplantation 2009; 88: 799-802.
14. Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, et al. Campath-1H (ALEMTUZUMAB) induction therapy in cadaveric kidney transplantation efficacy and safety at five years. Am J Transplant 2005; 5: 1347-1353.
15. Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric kidney transplantation. Am J Transplant 2005; 5: 1569-1573.
16. Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roohipour R, Carreno MR. The use of Campath-1H as induction therapy in kidney transplantation: preliminary results. Transplantation 2004; 78: 426-433.
17. Ortiz J, Palma-Vargas J, Wright F, Bingaman A, Agha I, Rosenblatt S, et al. Campath induction for kidney transplantation: report of 297 cases. Transplantation 2008; 85: 1550-1556.
18. Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infectious complications in adult kidney transplantation. Transplantation 2006; 81: 17-20.
19. Tan HP, Kaczorowski DJ, Basu A, Unruh M, McCauley J, Wu C, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6: 2409-2417.
20. Vathsala A, Ona ET, Tan SY, Suresh S, Lou HX, Casasola CB, et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80: 765-774.